Maximilian Alexander Röhnert

Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia

Christina Rautenberg, Friedrich Stölzel, Christoph Röllig et al. · Blood Cancer Journal · 2021 · 65 citations · Full text

Medicine, Hematology, Cancer Drug Toxicity Management +15

Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia

Maximilian Alexander Röhnert, Michael Krämer, Jonas Schadt et al. · Leukemia · 2022 · 25 citations · Full text

Medicine, Hematology, Oncology +13

The diagnostic red blood cell distribution width as a prognostic factor in acute myeloid leukemia

Vladan Vučinić, Leo Ruhnke, Katja Sockel et al. · Blood Advances · 2021 · 23 citations · Full text

Medicine, Hematology, Oncology +14

Identification of critical hemodilution by artificial intelligence in bone marrow assessed for minimal residual disease analysis in acute myeloid leukemia: The Cinderella method

Joerg Hoffmann, Michael C. Thrun, Maximilian Alexander Röhnert et al. · Cytometry Part A · 2022 · 15 citations · Full text

Medicine, Hematology, Oncology +17

Venetoclax Plus High-Dose Cytarabine and Mitoxantrone (HAM-Ven) As Salvage Treatment for Relapsed/Refractory AML: Updated Results of the Phase-I/II SAL Relax Trial

Leo Ruhnke, Christoph Schliemann, Jan‐Henrik Mikesch et al. · Blood · 2023 · 15 citations

Medicine, Oncology, Pharmacology +9